|
Abel EL, Angel JM, Kiguchi K, DiGiovanni J. Multi-stage chemical carcinogenesis in mouse skin: fundamentals and applications. Nat Protoc. 2009; 4: 1350-62.
Alison MR, Lim SM, Nicholson LJ. Cancer stem cells: problems for therapy? J Pathol. 2011; 223: 147-61.
Ananthakrishnan R, Ehrlicher A. The forces behind cell movement. Int J Biol Sci. 2007; 3: 303-17.
Anders CK, Winer EP, Ford JM, Dent R, Silver DP, Sledge GW, Carey LA. Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer. Clin Cancer Res. 2010; 16: 4702-10.
Andreu CI, Woehlbier U, Torres M, Hetz C. Protein disulfide isomerases in neurodegeneration: from disease mechanisms to biomedical applications. FEBS Lett. 2012; 586: 2826-34.
Anthis NJ, Wegener KL, Ye F, Kim C, Goult BT, Lowe ED, Vakonakis I, Bate N, Critchley DR, Ginsberg MH, Campbell ID. The structure of an integrin/talin complex reveals the basis of inside-out signal transduction. EMBO J. 2009; 28: 3623-32.
Aoudjit F, Vuori K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene. 2001; 20: 4995-5004.
Bail&;#243;n-Moscoso N, Romero-Benavides JC, Ostrosky-Wegman P. Development of anticancer drugs based on the hallmarks of tumor cells. Tumour Biol. 2014; 35: 3981-95.
Barczyk M, Carracedo S, Gullberg D. Integrins. Cell Tissue Res. 2010; 339: 269-80.
Beaty BT, Sharma VP, Bravo-Cordero JJ, Simpson MA, Eddy RJ, Koleske AJ, Condeelis J. β1 integrin regulates Arg to promote invadopodial maturation and matrix degradation. Mol Biol Cell. 2013; 24: 1661-75.
Benham AM. The protein disulfide isomerase family: key players in health and disease. Antioxid Redox Signal. 2012; 16: 781-9.
Bennett TA, Edwards BS, Sklar LA, Rogelj S. Sulfhydryl regulation of L-selectin shedding: phenylarsine oxide promotes activation-independent L-selectin shedding from leukocytes. J Immunol. 2000; 164: 4120-9.
Bi S, Hong PW, Lee B, Baum LG. Galectin-9 binding to cell surface protein disulfide isomerase regulates the redox environment to enhance T-cell migration and HIV entry. Proc Natl Acad Sci U S A. 2011; 108: 10650-5.
B&;#246;ttcher RT, Lange A, F&;#228;ssler R. How ILK and kindlins cooperate to orchestrate integrin signaling. Curr Opin Cell Biol. 2009; 21: 670-5
Bramati A, Girelli S, Torri V, Farina G, Galfrascoli E, Piva S, Moretti A, Dazzani MC, Sburlati P, La Verde NM. Efficacy of biological agents in metastatic triple-negative breast cancer. Cancer Treat Rev. 2014; 40: 605-13.
Byron A, Humphries JD, Askari JA, Craig SE, Mould AP, Humphries MJ. Anti-integrin monoclonal antibodies. J Cell Sci. 2009; 122: 4009-11.
Cai X, Lietha D, Ceccarelli DF, Karginov AV, Rajfur Z, Jacobson K, Hahn KM, Eck MJ, Schaller MD. Spatial and temporal regulation of focal adhesion kinase activity in living cells. Mol Cell Biol. 2008; 28: 201-14.
Calderwood DA, Campbell ID, Critchley DR. Talins and kindlins: partners in integrin-mediated adhesion. Nat Rev Mol Cell Biol. 2013; 14: 503-17.
Calderwood DA, Shattil SJ, Ginsberg MH. Integrins and actin filaments: reciprocal regulation of cell adhesion and signaling. J Biol Chem. 2000; 275: 22607-10.
Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295: 2492-502.
Carter KC, Finnon YS, Daeid NN, Robson DC, Waddell R. The effect of nitrostyrene on cell proliferation and macrophage immune responses. Immunopharmacol Immunotoxicol. 2002; 24: 187-97.
Chou TF, Deshaies RJ. Quantitative cell-based protein degradation assays to identify and classify drugs that target the ubiquitin-proteasome system. J Biol Chem. 2011; 286: 16546-54.
Clark O, Botrel TE, Paladini L, Ferreira MB. Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis. Core Evid. 2014; 9: 1-11.
Coffelt SB, Hughes R, Lewis CE. Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim Biophys Acta. 2009; 1796: 11-8.
Damiano JS. Integrins as novel drug targets for overcoming innate drug resistance. Curr Cancer Drug Targets. 2002; 2: 37-43.
Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M; Comparative Risk Assessment collaborating group (Cancers). Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet. 2005; 366: 1784-93.
Dank M, Budi L, Piko B, Mangel L, Erfan J, Cseh J, Ruzsa A, Landherr L. First-line bevacizumab-paclitaxel in 220 patients with metastatic breast cancer: results from the AVAREG study. Anticancer Res. 2014; 34: 1275-80.
Davis GE, Camarillo CW. Regulation of integrin-mediated myeloid cell adhesion to fibronectin: influence of disulfide reducing agents, divalent cations and phorbol ester. J Immunol. 1993; 151: 7138-50.
Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005; 5: 275-84.
Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13: 4429-34.
Deramaudt TB, Dujardin D, Noulet F, Martin S, Vauchelles R, Takeda K, Rond&;#233; P. Altering FAK-paxillin interactions reduces adhesion, migration and invasion processes. PLoS One. 2014; 9:e92059.
DiGiovanni J. Multistage carcinogenesis in mouse skin. Pharmacol Ther. 1992; 54: 63-128.
Diwaker D, Mishra KP, Ganju L, Singh SB. Protein disulfide isomerase mediates dengue virus entry in association with lipid rafts. Viral Immunol. 2015; 28: 153-60.
Essex DW. The role of thiols and disulfides in platelet function. Antioxid Redox Signal. 2004; 6: 736-46.
Fidler IJ. Metastasis: guantitative analysis of distribution and fate of tumor embolilabeled with 125 I-5-iodo-2''-deoxyuridine. J Natl Cancer Inst. 1970; 45: 773-82.
Fidler IJ. The pathogenesis of cancer metastasis: the ''seed and soil'' hypothesis revisited. Nat Rev Cancer. 2003; 3: 453-8.
Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med. 2010; 363: 1938-48.
Frame MC, Patel H, Serrels B, Lietha D, Eck MJ. The FERM domain: organizing the structure and function of FAK. Nat Rev Mol Cell Biol. 2010; 11: 802-14.
Freedman RB, Hirst TR, Tuite MF. Protein disulphide isomerase: building bridges in protein folding. Trends Biochem Sci. 1994; 19: 331-6.
Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell. 2011; 147: 992-1009.
Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat Rev Cancer. 2003; 3: 362-74.
Gabarra-Niecko V, Schaller MD, Dunty JM. FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metastasis Rev. 2003; 22: 359-74.
Gavert N, Ben-Ze''ev A. Epithelial-mesenchymal transition and the invasive potential of tumors. Trends Mol Med. 2008; 14: 199-209.
Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011; 11: 123-34.
Giancotti FG, Ruoslahti E. Integrin signaling. Science. 1999; 285: 1028-32.
Giancotti FG. A structural view of integrin activation and signaling. Dev Cell. 2003; 4: 149-51.
Giannoni E, Bianchini F, Masieri L, Serni S, Torre E, Calorini L, Chiarugi P. Reciprocal activation of prostate cancer cells and cancer-associated fibroblasts stimulates epithelial-mesenchymal transition and cancer stemness. Cancer Res. 2010; 70: 6945-56.
Goldberger RF, Epstein CJ, Anfinsen CB. Acceleration of reactivation of reduced bovine pancreatic ribonuclease by a microsomal system from rat liver. J Biol Chem. 1963; 238: 628-35.
Gonz&;#225;lez-Santiago L, Alfonso P, Su&;#225;rez Y, N&;#250;&;#241;ez A, Garc&;#237;a-Fern&;#225;ndez LF, Alvarez E, Mu&;#241;oz A, Casal JI. Proteomic analysis of the resistance to aplidin in human cancer cells. J Proteome Res. 2007; 6: 1286-94.
Goplen D, Wang J, Enger P&;#216;, Tysnes BB, Terzis AJ, Laerum OD, Bjerkvig R. Protein disulfide isomerase expression is related to the invasive properties of malignant glioma. Cancer Res. 2006; 66: 9895-902.
Grek C, Townsend DM. Protein Disulfide Isomerase Superfamily in Disease and the Regulation of Apoptosis. Endoplasmic Reticulum Stress Dis. 2014; 1: 4-17.
Gruber CW, Cemazar M, Heras B, Martin JL, Craik DJ. Protein disulfide isomerase: the structure of oxidative folding. Trends Biochem Sci. 2006; 31: 455-64.
Guddati AK. Ovarian cancer stem cells: elusive targets for chemotherapy. Med Oncol. 2012; 29: 3400-8.
Gumireddy K, Sun F, Klein-Szanto AJ, Gibbins JM, Gimotty PA, Saunders AJ, Schultz PG, Huang Q. In vivo selection for metastasis promoting genes in the mouse. Proc Natl Acad Sci U S A. 2007; 104: 6696-701.
Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol. 2004; 5: 816-26.
Hahm E, Li J, Kim K, Huh S, Rogelj S, Cho J. Extracellular protein disulfide isomerase regulates ligand-binding activity of αMβ2 integrin and neutrophil recruitment during vascular inflammation. Blood. 2013; 121: 3789-800, S1-15.
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100: 57-70.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144: 646-74.
Hartge P. Genes, hormones, and pathways to breast cancer. N Engl J Med. 2003; 348: 2352-4.
Hashida T, Kotake Y, Ohta S. Protein disulfide isomerase knockdown-induced cell death is cell-line-dependent and involves apoptosis in MCF-7 cells. J Toxicol Sci. 2011; 36: 1-7.
Hatahet F, Ruddock LW. Protein disulfide isomerase: a critical evaluation of its function in disulfide bond formation. Antioxid Redox Signal. 2009; 11: 2807-50.
Hato T, Pampori N, Shattil SJ. Complementary roles for receptor clustering and conformational change in the adhesive and signaling functions of integrin αIIbβ3. J Cell Biol. 1998; 141: 1685-95.
He Y, Varadarajan S, Mu&;#241;oz-Planillo R, Burberry A, Nakamura Y, N&;#250;&;#241;ez G. 3,4-methylenedioxy-β-nitrostyrene inhibits NLRP3 inflammasome activation by blocking assembly of the inflammasome. J Biol Chem. 2014; 289: 1142-50.
Holmgren A. Thioredoxin catalyzes the reduction of insulin disulfides by dithiothreitol and dihydrolipoamide. J Biol Chem. 1979; 254: 9627-9632.
Horibe T, Torisawa A, Okuno Y, Kawakami K. Discovery of protein disulfide isomerase P5 inhibitors that reduce the secretion of MICA from cancer cells. Chembiochem. 2014; 15: 1599-606.
Hsieh PW, Chang YT, Chuang WY, Shih HC, Chiang SZ, Wu CC. The synthesis and biologic evaluation of anti-platelet and cytotoxic β-nitrostyrenes. Bioorg Med Chem. 2010; 18: 7621-7.
Hsu MY, Shih DT, Meier FE, Van Belle P, Hsu JY, Elder DE, Buck CA, Herlyn M. Adenoviral gene transfer of β3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. Am J Pathol. 1998; 153: 1435-42.
Huang C, Park CC, Hilsenbeck SG, Ward R, Rimawi MF, Wang YC, Shou J, Bissell MJ, Osborne CK, Schiff R. β1 integrin mediates an alternative survival pathway in breast cancer cells resistant to lapatinib. Breast Cancer Res. 2011; 13: R84.
Huck L, Pontier SM, Zuo DM, Muller WJ. beta1-integrin is dispensable for the induction of ErbB2 mammary tumors but plays a critical role in the metastatic phase of tumor progression. Proc Natl Acad Sci U S A. 2010; 107: 15559-64.
Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist. 2011; 16 Suppl 1:1-11.
Humphries MJ, Mould AP. Structure. An anthropomorphic integrin. Science. 2001; 294: 316-7.
Humphries MJ, Symonds EJ, Mould AP. Mapping functional residues onto integrin crystal structures. Curr Opin Struct Biol. 2003; 13: 236-43.
Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell. 2002; 110: 673-87
Isakoff SJ. Triple-negative breast cancer: role of specific chemotherapy agents. Cancer J. 2010; 16: 53-61.
Ivascu A, Kubbies M. Diversity of cell-mediated adhesions in breast cancer spheroids. Int J Oncol. 2007; 31: 1403-13.
Jiang XM, Fitzgerald M, Grant CM, Hogg PJ. Redox control of exofacial protein thiols/disulfides by protein disulfide isomerase. J Biol Chem. 1999; 274: 2416-23.
Jin H, Varner J. Integrins: roles in cancer development and as treatment targets. Br J Cancer. 2004; 90: 561-5.
Jordan PA, Gibbins JM. Extracellular disulfide exchange and the regulation of cellular function. Antioxid Redox Signal. 2006; 8: 312-24.
Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer. 2009; 9: 239-52.
Kaap S, Quentin I, Tamiru D, Shaheen M, Eger K, Steinfelder HJ. Structure activity analysis of the pro-apoptotic, antitumor effect of nitrostyrene adducts and related compounds. Biochem Pharmacol. 2003; 65: 603-10.
Kaiser BK, Yim D, Chow IT, Gonzalez S, Dai Z, Mann HH, Strong RK, Groh V, Spies T. Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature. 2007; 447: 482-6.
Kanner SB, Reynolds AB, Vines RR, Parsons JT. Monoclonal antibodies to individual tyrosine-phosphorylated protein substrates of oncogene-encoded tyrosine kinases. Proc Natl Acad Sci U S A. 1990; 87: 3328-32.
Kaverina I, Krylyshkina O, Small JV. Regulation of substrate adhesion dynamics during cell motility. Int J Biochem Cell Biol. 2002; 34: 746-61.
Kemmink J, Darby NJ, Dijkstra K, Nilges M, Creighton TE. The folding catalyst protein disulfide isomerase is constructed of active and inactive thioredoxin modules. Curr Biol. 1997; 7: 239-45.
Kerbel RS. Tumor angiogenesis. N Engl J Med. 2008; 358: 2039-49.
Key TJ, Schatzkin A, Willett WC, Allen NE, Spencer EA, Travis RC. Diet, nutrition and the prevention of cancer. Public Health Nutr. 2004; 7: 187-200.
Khan MM, Simizu S, Lai NS, Kawatani M, Shimizu T, Osada H. Discovery of a small molecule PDI inhibitor that inhibits reduction of HIV-1 envelope glycoprotein gp120. ACS Chem Biol. 2011; 6: 245-51.
Khan MM, Simizu S, Suzuki T, Masuda A, Kawatani M, Muroi M, Dohmae N, Osada H. Protein disulfide isomerase-mediated disulfide bonds regulate the gelatinolytic activity and secretion of matrix metalloproteinase-9. Exp Cell Res. 2012; 318: 904-14.
Kim JH, Kim JH, Lee GE, Lee JE, Chung IK. Potent inhibition of human telomerase by nitrostyrene derivatives. Mol Pharmacol. 2003; 63: 1117-24.
Kinashi T. Intracellular signalling controlling integrin activation in lymphocytes. Nat Rev Immunol. 2005; 5: 546-59.
Kozlov G, M&;#228;&;#228;tt&;#228;nen P, Thomas DY, Gehring K. A structural overview of the PDI family of proteins. FEBS J. 2010; 277: 3924-36.
Kratimenos P, Koutroulis I, Marconi D, Syriopoulou V, Delivoria-Papadopoulos M, Chrousos GP, Theocharis S. Multi-targeted molecular therapeutic approach in aggressive neuroblastoma: the effect of Focal Adhesion Kinase-Src-Paxillin system. Expert Opin Ther Targets. 2014; 18: 1395-406.
Kryczka J, Stasiak M, Dziki L, Mik M, Dziki A, Cierniewski C. Matrix metalloproteinase-2 cleavage of the β1 integrin ectodomain facilitates colon cancer cell motility. J Biol Chem. 2012; 287: 36556-66.
Kumar R, Sharma A, Tiwari RK. Application of microarray in breast cancer: An overview. J Pharm Bioallied Sci. 2012; 4: 21-6.
Lahav J, Jurk K, Hess O, Barnes MJ, Farndale RW, Luboshitz J, Kehrel BE. Sustained integrin ligation involves extracellular free sulfhydryls and enzymatically catalyzed disulfide exchange. Blood. 2002; 100: 2472-8.
Lahav J, Wijnen EM, Hess O, Hamaia SW, Griffiths D, Makris M, Knight CG, Essex DW, Farndale RW. Enzymatically catalyzed disulfide exchange is required for platelet adhesion to collagen via integrin alpha2beta1. Blood. 2003; 102: 2085-92.
Lahlou H, Muller WJ. β1-integrins signaling and mammary tumor progression in transgenic mouse models: implications for human breast cancer. Breast Cancer Res. 2011; 13: 229.
LaMantia M, Miura T, Tachikawa H, Kaplan HA, Lennarz WJ, Mizunaga T. Glycosylation site binding protein and protein disulfide isomerase are identical and essential for cell viability in yeast. Proc Natl Acad Sci U S A. 1991; 88: 4453-7.
Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, Dick JE. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994; 367: 645-8.
Legate KR, Wickstr&;#246;m SA, F&;#228;ssler R. Genetic and cell biological analysis of integrin outside-in signaling. Genes Dev. 2009; 23: 397-418
Leitinger B, McDowall A, Stanley P, Hogg N. he regulation of integrin function by Ca2+. Biochim Biophys Acta. 2000; 1498: 91-8.
Lesniak D, Xu Y, Deschenes J, Lai R, Thoms J, Murray D, Gosh S, Mackey JR, Sabri S, Abdulkarim B. Beta1-integrin circumvents the antiproliferative effects of trastuzumab in human epidermal growth factor receptor-2-positive breast cancer. Cancer Res. 2009; 69: 8620-8.
Lewis CE, Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006; 66: 605-12.
Li DM, Feng YM. Signaling mechanism of cell adhesion molecules in breast cancer metastasis: potential therapeutic targets. Breast Cancer Res Treat. 2011; 128: 7-21.
Lietha D, Cai X, Ceccarelli DF, Li Y, Schaller MD, Eck MJ. Structural basis for the autoinhibition of focal adhesion kinase. Cell. 2007; 129: 1177-87.
Lock JG, Wehrle-Haller B, Str&;#246;mblad S. Cell-matrix adhesion complexes: master control machinery of cell migration. Semin Cancer Biol. 2008; 18: 65-76.
Lovat PE, Corazzari M, Armstrong JL, Martin S, Pagliarini V, Hill D, Brown AM, Piacentini M, Birch-Machin MA, Redfern CP. Increasing melanoma cell death using inhibitors of protein disulfide isomerases to abrogate survival responses to endoplasmic reticulum stress. Cancer Res. 2008; 68: 5363-9.
Lundstr&;#246;m A, Holmbom J, Lindqvist C, Nordstr&;#246;m T. The role of alpha2 beta1 and alpha3 beta1 integrin receptors in the initial anchoring of MDA-MB-231 human breast cancer cells to cortical bone matrix. Biochem Biophys Res Commun. 1998; 250: 735-40.
Luque A, G&;#243;mez M, Puzon W, Takada Y, S&;#225;nchez-Madrid F, Caba&;#241;as C. Activated conformations of very late activation integrins detected by a group of antibodies (HUTS) specific for a novel regulatory region (355-425) of the common beta 1 chain. J Biol Chem. 1996; 271: 11067-75.
Mandel R, Ryser HJ, Ghani F, Wu M, Peak D. Inhibition of a reductive function of the plasma membrane by bacitracin and antibodies against protein disulfide-isomerase. Proc Natl Acad Sci U S A. 1993; 90: 4112-6.
Manickam N, Sun X, Li M, Gazitt Y, Essex DW. Protein disulphide isomerase in platelet function. Br J Haematol. 2008; 140: 223-9.
Mas-Moruno C, Rechenmacher F, Kessler H. Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem. 2010; 10: 753-68.
Margadant C, Monsuur HN, Norman JC, Sonnenberg A. Mechanisms of integrin activation and trafficking. Curr Opin Cell Biol. 2011; 23: 607-14.
McEver RP. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost. 2001; 86: 746-56.
McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, Frame MC. The role of focal-adhesion kinase in cancer - a new therapeutic opportunity. Nat Rev Cancer. 2005; 5: 505-15.
Messerschmitt PJ, Rettew AN, Schroeder NO, Brookover RE, Jakatdar AP, Getty PJ, Greenfield EM. Osteosarcoma Phenotype Is Inhibited by 3,4-Methylenedioxy-β-nitrostyrene. Sarcoma.2012; 2012:479712.
Milhazes N, Calheiros R, Marques MP, Garrido J, Cordeiro MN, Rodrigues C, Quinteira S, Novais C, Peixe L, Borges F. Beta-nitrostyrene derivatives as potential antibacterial agents: a structure-property-activity relationship study. Bioorg Med Chem. 2006; 14: 4078-88.
Mitra SK, Hanson DA, Schlaepfer DD. Focal adhesion kinase: in command and control of cell motility. Nat Rev Mol Cell Biol. 2005; 6: 56-68.
Mitra SK, Schlaepfer DD. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol. 2006; 18: 516-23.
Montano SJ, Lu J, Gustafsson TN, Holmgren A. Activity assays of mammalian thioredoxin and thioredoxin reductase: fluorescent disulfide substrates, mechanisms, and use with tissue samples. Anal Biochem. 2014; 449: 139-146.
Morozevich G, Kozlova N, Cheglakov I, Ushakova N, Berman A. Integrin alpha5beta1 controls invasion of human breast carcinoma cells by direct and indirect modulation of MMP-2 collagenase activity. Cell Cycle. 2009; 8: 2219-25.
Mou Y, Ni H, Wilkins JA. The selective inhibition of beta 1 and beta 7 integrin-mediated lymphocyte adhesion by bacitracin. J Immunol. 1998; 161: 6323-9.
Mueller MM, Fusenig NE. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat Rev Cancer. 2004; 4: 839-49.
Nagano M, Hoshino D, Koshikawa N, Akizawa T, Seiki M. Turnover of focal adhesions and cancer cell migration. Int J Cell Biol. 2012; 2012:310616.
Nam JM, Chung Y, Hsu HC, Park CC. beta1 integrin targeting to enhance radiation therapy. Int J Radiat Biol. 2009; 85: 923-8.
Ni H, Li A, Simonsen N, Wilkins JA. Integrin activation by dithiothreitol or Mn2+ induces a ligand-occupied conformation and exposure of a novel NH2-terminal regulatory site on the beta1 integrin chain. J Biol Chem. 1998; 273: 7981-7.
Nicolini A, Ferrari P, Fini M, Borsari V, Fallahi P, Antonelli A, Berti P, Carpi A, Miccoli P. Stem cells: their role in breast cancer development and resistance to treatment. Curr Pharm Biotechnol. 2011; 12: 96-205.
Nishida N, Xie C, Shimaoka M, Cheng Y, Walz T, Springer TA. Activation of leukocyte beta2 integrins by conversion from bent to extended conformations. Immunity. 2006; 25: 583-94.
Noiva R. Protein disulfide isomerase: the multifunctional redox chaperone of the endoplasmic reticulum. Semin Cell Dev Biol. 1999; 10: 481-93.
Owens LV, Xu L, Craven RJ, Dent GA, Weiner TM, Kornberg L, Liu ET, Cance WG. Overexpression of the focal adhesion kinase (p125FAK) in invasive human tumors. Cancer Res. 1995; 55: 2752-5.
Paget, S. The distribution of secondary growths in cancer of the breast. Lancet. 1889; 1: 571–573.
Palomba G, Budroni M, Olmeo N, Atzori F, Ionta MT, Pisano M, Tanda F, Cossu A, Palmieri G. Triple-negative breast cancer frequency and type of BRCA mutation: Clues from Sardinia. Oncol Lett. 2014; 7: 948-952.
Parakh S, Atkin JD. Novel roles for protein disulphide isomerase in disease states: a double edged sword? Front Cell Dev Biol. 2015; 3:30.
Park CC, Zhang H, Pallavicini M, Gray JW, Baehner F, Park CJ, Bissell MJ. Beta1 integrin inhibitory antibody induces apoptosis of breast cancer cells, inhibits growth, and distinguishes malignant from normal phenotype in three dimensional cultures and in vivo. Cancer Res. 2006; 66: 1526-1535.
Park Y, Moriyama A, Kitahara T, Yoshida Y, Urita T, Kato R. Triple-negative breast cancer and poly(ADP-ribose) polymerase inhibitors. Anticancer Agents Med Chem. 2012; 12: 672-7.
Parsons JT. Focal adhesion kinase: the first ten years. J Cell Sci. 2003; 116: 1409-16.
Parsons JT, Martin KH, Slack JK, Taylor JM, Weed SA. Focal adhesion kinase: a regulator of focal adhesion dynamics and cell movement. Oncogene. 2000; 19: 5606-13.
Parsons JT, Slack-Davis J, Tilghman R, Roberts WG. Focal adhesion kinase: targeting adhesion signaling pathways for therapeutic intervention. Clin Cancer Res. 2008; 14: 627-32.
Pellinen T, Rantala JK, Arjonen A, Mpindi JP, Kallioniemi O, Ivaska J. A functional genetic screen reveals new regulators of β1-integrin activity. J Cell Sci. 2012; 125: 649-61.
Pettit RK, Pettit GR, Hamel E, Hogan F, Moser BR, Wolf S, Pon S, Chapuis JC, Schmidt JM. E-Combretastatin and E-resveratrol structural modifications: antimicrobial and cancer cell growth inhibitory beta-E-nitrostyrenes. Bioorg Med Chem. 2009; 17: 6606-12.
Pierce A, McGowan PM, Cotter M, Mullooly M, O''Donovan N, Rani S, O''Driscoll L, Crown J, Duffy MJ. Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines. Cancer Biol Ther. 2013; 14: 537-45.
Pi&;#281;ta B, Chmaj-Wierzchowska K, Opala T. Life style and risk of development of breast and ovarian cancer. Ann Agric Environ Med. 2012; 19: 379-84.
Pinedo HM, Verheul HM, D''Amato RJ, Folkman J. Involvement of platelets in tumour angiogenesis ? Lancet. 1998; 352: 1775-7.
Playford MP, Schaller MD. The interplay between Src and integrins in normal and tumor biology. Oncogene. 2004; 23: 7928-46.
Polanska UM, Orimo A. Carcinoma-associated fibroblasts: non-neoplastic tumour-promoting mesenchymal cells. J Cell Physiol. 2013; 228: 1651-7
Raturi A, Mutus B. Characterization of redox state and reductase activity of protein disulfide isomerase under different redox environments using a sensitive fluorescent assay. Free Radic Biol Med. 2007; 43: 62-70.
Reardon DA, Neyns B, Weller M, Tonn JC, Nabors LB, Stupp R. Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies. Future Oncol. 2011; 7: 339-54.
Rosan&;#242; L, Spinella F, Bagnato A. Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2013; 13: 637-51.
Rosso F, Giordano A, Barbarisi M, Barbarisi A. From cell-ECM interactions to tissue engineering. J Cell Physiol. 2004; 199: 174-80.
Sameni M1, Dosescu J, Yamada KM, Sloane BF, Cavallo-Medved D. Functional live-cell imaging demonstrates that beta1-integrin promotes type IV collagen degradation by breast and prostate cancer cells. Mol Imaging. 2008; 7: 199-213.
Sasaki, T., Timpl, R., Laminins, T. K., &; Vale, R. Guidebook to the Extracellular Matrix, Anchor, and Adhesion Proteins. Sambook and Tooze Publication at Oxford University Press. 1999; 434-443.
Sawhney RS, Cookson MM, Omar Y, Hauser J, Brattain MG. Integrin α2-mediated ERK and calpain activation play a critical role in cell adhesion and motility via focal adhesion kinase signaling: identification of a novel signaling pathway. J Biol Chem. 2006; 281: 8497-510.
Schedin P, Borges V. Breaking down barriers: the importance of the stromal microenvironment in acquiring invasiveness in young women''s breast cancer. Breast Cancer Res. 2009; 11:102.
Schlaepfer DD, Mitra SK, Ilic D. Control of motile and invasive cell phenotypes by focal adhesion kinase. Biochim Biophys Acta. 2004; 1692: 77-102.
Schmidmaier R, Baumann P. ANTI-ADHESION evolves to a promising therapeutic concept in oncology. Curr Med Chem. 2008; 15: 978-90.
Shan D, Li J, Cai P, Prasad P, Liu F, Rauth AM, Wu XY. RGD-conjugated solid lipid nanoparticles inhibit adhesion and invasion of αvβ3 integrin-overexpressing breast cancer cells. Drug Deliv Transl Res. 2015; 5: 15-26.
Shanthi E, Krishna MH, Arunesh GM, Venkateswara Reddy K, Sooriya Kumar J, Viswanadhan VN. Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review. Expert Opin Ther Pat. 2014; 24: 1077-100.
Shattil SJ, Kim C, Ginsberg MH. The final steps of integrin activation: the end game. Nat Rev Mol Cell Biol. 2010; 11: 288-300.
Shimaoka M, Lu C, Salas A, Xiao T, Takagi J, Springer TA. Stabilizing the integrin alpha M inserted domain in alternative conformations with a range of engineered disulfide bonds. Proc Natl Acad Sci U S A. 2002; 99: 16737-41.
Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH, Schlaepfer DD. FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol. 2000; 2: 249-56.
Siesser PM, Hanks SK. The signaling and biological implications of FAK overexpression in cancer. Clin Cancer Res. 2006; 12: 3233-7.
Simonsen TG, Gaustad JV, Leinaas MN, Rofstad EK. High interstitial fluid pressure is associated with tumor-line specific vascular abnormalities in human melanoma xenografts. PLoS One. 2012; 7: e40006.
Singh A, Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010; 29: 4741-51.
Slack-Davis JK, Martin KH, Tilghman RW, Iwanicki M, Ung EJ, Autry C, Luzzio MJ, Cooper B, Kath JC, Roberts WG, Parsons JT. Cellular characterization of a novel focal adhesion kinase inhibitor. J Biol Chem. 2007; 282: 14845-52.
Smith AM, Chan J, Oksenberg D, Urfer R, Wexler DS, Ow A, Gao L, McAlorum A, Huang SG. A high-throughput turbidometric assay for screening inhibitors of protein disulfide isomerase activity. J Biomol Screen. 2004; 9: 614-20.
Song H, Cha MJ, Song BW, Kim IK, Chang W, Lim S, Choi EJ, Ham O, Lee SY, Chung N, Jang Y, Hwang KC. Reactive oxygen species inhibit adhesion of mesenchymal stem cells implanted into ischemic myocardium via interference of focal adhesion complex. Stem Cells. 2010; 28: 555-63
Steeg PS. Cancer biology: emissaries set up new sites. Nature. 2005; 438: 750-1.
Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006; 12: 895-904.
Subauste MC, Pertz O, Adamson ED, Turner CE, Junger S, Hahn KM. Vinculin modulation of paxillin-FAK interactions regulates ERK to control survival and motility. J Cell Biol. 2004; 165: 371-81.
Sulzmaier FJ, Jean C, Schlaepfer DD. FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer. 2014; 14: 598-610.
T&;#228;ger M, Kr&;#246;ning H, Thiel U, Ansorge S. Membrane-bound proteindisulfide isomerase (PDI) is involved in regulation of surface expression of thiols and drug sensitivity of B-CLL cells. Exp Hematol. 1997; 25: 601-7.
Takada Y, Ye X, Simon S. The integrins. Genome Biol. 2007; 8: 215.
Takagi J, Beglova N, Yalamanchili P, Blacklow SC, Springer TA. Definition of EGF-like, closely interacting modules that bear activation epitopes in integrin beta subunits. Proc Natl Acad Sci U S A. 2001; 98: 11175-80.
Takagi J, Petre BM, Walz T, Springer TA. Global conformational rearrangements in integrin extracellular domains in outside-in and inside-out signaling. Cell. 2002; 110: 599-11.
Tamkun JW, DeSimone DW, Fonda D, Patel RS, Buck C, Horwitz AF, Hynes RO. Structure of integrin, a glycoprotein involved in the transmembrane linkage between fibronectin and actin. Cell. 1986; 46: 271-82.
Thews O, Lambert C, Kelleher DK, Biesalski HK, Vaupel P, Frank J. Impact of therapeutically induced reactive oxygen species and radical scavenging by alpha-tocopherol on tumor cell adhesion. Oncol Rep. 2007; 18: 965-71.
Thiery JP. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002; 2: 442-54.
Thomas DA, Massagu&;#233; J. TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell. 2005; 8: 369-80.
Thompson R. Preventing cancer: the role of food, nutrition and physical activity. J Fam Health Care. 2010; 20: 100-2.
Thongwatchara P, Promwikorn W, Srisomsap C, Chokchaichamnankit D, Boonyaphiphat P, Thongsuksai P. Differential protein expression in primary breast cancer and matched axillary node metastasis. Oncol Rep. 2011; 26: 185-91.
Turano C, Coppari S, Altieri F, Ferraro A. Proteins of the PDI family: unpredicted non-ER locations and functions. J Cell Physiol. 2002; 193: 154-63.
Turner CE. Paxillin interactions. J Cell Sci. 2000; 113: 4139-40.
van der Pluijm, Vloedgraven H, Papapoulos S, L&;#246;wick C, Grzesik W, Kerr J, Robey PG. Attachment characteristics and involvement of integrins in adhesion of breast cancer cell lines to extracellular bone matrix components. Lab Invest. 1997; 77: 665-75.
van de Vijver MJ, He YD, van''t Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347:1999-2009.
van der Voort van Zyp J, Conway WC, Thamilselvan V, Polin L, Basson MD. Divalent cations influence colon cancer cell adhesion in a murine transplantable tumor model. Am J Surg. 2005; 190: 701-7.
Vollebergh MA, Lips EH, Nederlof PM, Wessels LF, Wesseling J, Vd Vijver MJ, de Vries EG, van Tinteren H, Jonkers J, Hauptmann M, Rodenhuis S, Linn SC. Genomic patterns resembling BRCA1- and BRCA2-mutated breast cancers predict benefit of intensified carboplatin-based chemotherapy. Breast Cancer Res. 2014; 16: R47.
Vuong D, Simpson PT, Green B, Cummings MC, Lakhani SR. Molecular classification of breast cancer. Virchows Arch. 2014; 465: 1-14.
Wang WY, Hsieh PW, Wu YC, Wu CC. Synthesis and pharmacological evaluation of novel beta-nitrostyrene derivatives as tyrosine kinase inhibitors with potent antiplatelet activity. Biochem Pharmacol. 2007; 74: 601-11.
Wang WY, Wu YC, Wu CC. Prevention of platelet glycoprotein IIb/IIIa activation by 3,4-methylenedioxy-beta-nitrostyrene, a novel tyrosine kinase inhibitor. Mol Pharmacol. 2006; 70: 1380-9.
Watanabe MM, Laurindo FR, Fernandes DC. Methods of measuring protein disulfide isomerase activity: a critical overview. Front Chem. 2014; 2: 73.
Wei Y, Czekay RP, Robillard L, Kugler MC, Zhang F, Kim KK, Xiong JP, Humphries MJ, Chapman HA. Regulation of α5β1 integrin conformation and function by urokinase receptor binding. J Cell Biol. 2005; 168: 501-11.
Whiteside TL. The tumor microenvironment and its role in promoting tumor growth. Oncogene. 2008; 27: 5904-12.
Willems SH, Tape CJ, Stanley PL, Taylor NA, Mills IG, Neal DE, McCafferty J, Murphy G. Thiol isomerases negatively regulate the cellular shedding activity of ADAM17. Biochem J. 2010; 428: 439-50.
Xu S, Butkevich AN, Yamada R, Zhou Y, Debnath B, Duncan R, Zandi E, Petasis NA, Neamati N. Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase for ovarian cancer treatment. Proc Natl Acad Sci U S A. 2012; 109: 16348-53.
Xu S, Sankar S, Neamati N. Protein disulfide isomerase: a promising target for cancer therapy. Drug Discov Today. 2014; 19: 222-40.
Yamaguchi H, Wyckoff J, Condeelis J. Cell migration in tumors. Curr Opin Cell Biol. 2005; 17: 559-64.
Yan B, Smith JW. Mechanism of integrin activation by disulfide bond reduction. Biochemistry. 2001; 40: 8861-7.
Yao D, Dai C, Peng S. Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation. Mol Cancer Res. 2011; 9: 1608-20.
Yao ES, Zhang H, Chen YY, Lee B, Chew K, Moore D, Park C. Increased beta1 integrin is associated with decreased survival in invasive breast cancer. Cancer Res. 2007; 67: 659-64.
Yao H, Veine DM, Fay KS, Staszewski ED, Zeng ZZ, Livant DL. The PHSCN dendrimer as a more potent inhibitor of human breast cancer cell invasion, extravasation, and lung colony formation. Breast Cancer Res Treat. 2011; 125: 363-75.
Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009; 28: 15-33.
Yoon H, Dehart JP, Murphy JM, Lim ST. Understanding the roles of FAK in cancer: inhibitors, genetic models, and new insights. J Histochem Cytochem. 2015; 63: 114-28.
Yu T, Wu X, Gupta KB, Kucik DF. Affinity, lateral mobility, and clustering contribute independently to β2-integrin-mediated adhesion. Am J Physiol Cell Physiol. 2010; 299: C399-410.
Yu Y, Xiao CH, Tan LD, Wang QS, Li XQ, Feng YM. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-β signalling. Br J Cancer. 2014; 110: 724-32.
Yuan A, Chen JJ, Yang PC. Pathophysiology of tumor-associated macrophages. Adv Clin Chem. 2008; 45: 199-223.
Zaidel-Bar R, Milo R, Kam Z, Geiger B. A paxillin tyrosine phosphorylation switch regulates the assembly and form of cell-matrix adhesions. J Cell Sci. 2007; 120: 137-48.
Zhang Q1, Yang X, Pins M, Javonovic B, Kuzel T, Kim SJ, Parijs LV, Greenberg NM, Liu V, Guo Y, Lee C. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. Cancer Res. 2005; 65: 1761-9.
Zhao J, Guan JL. Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev. 2009; 28: 35-49.
Zhao X, Guan JL. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Adv Drug Deliv Rev. 2011; 63: 610-5.
Zhou J, Chen Y, Lang JY, Lu JJ, Ding J. Salvicine inactivates beta 1 integrin and inhibits adhesion of MDA-MB-435 cells to fibronectin via reactive oxygen species signaling. Mol Cancer Res. 2008; 6: 194-204.
Zong J, Guo C, Liu S, Sun MZ, Tang J. Proteomic research progress in lymphatic metastases of cancers. Clin Transl Oncol. 2012; 14: 21-30.
|